Resolution of Protein-Losing Enteropathy after Congenital Heart Disease Repair by Selective Lymphatic Embolization

Ranjit I Kylat, Marlys H Witte, Brent J Barber, Yoav Dori, and Fayez K Ghishan

1Department of Pediatrics, The University of Arizona College of Medicine, Tucson, AZ, USA
2Department of Surgery, The University of Arizona College of Medicine, Tucson, AZ, USA
3Center for Lymphatic Imaging and Interventions, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

ABSTRACT

With improving survival of children with complex congenital heart disease (CCHD), postoperative complications, like protein-losing enteropathy (PLE) are increasingly encountered. A 3-year-old girl with surgically corrected CCHD (ventricular inversion/L-transposition of the great arteries, ventricular septal defect, pulmonary atresia, post-double switch procedure [Rastelli and Glenn]) developed chylothoraces. She was treated with pleurodesis, thoracic duct ligation and subsequently developed chylous ascites and PLE (serum albumin ≤0.9 g/dL) and was malnourished, despite nutritional rehabilitation. Lymphangioscintigraphy/single-photon emission computed tomography showed lymphatic obstruction at the cisterna chyli level. A segmental chyle leak and chylous lymphangiectasia were confirmed by gastrointestinal endoscopy, magnetic resonance (MR) enterography, and MR lymphangiography. Selective glue embolization of leaking intestinal lymphatic trunks led to prompt reversal of PLE. Serum albumin level and weight gain markedly improved and have been maintained for over 3 years. Selective interventional embolization reversed this devastating lymphatic complication of surgically corrected CCHD.

Keywords: Protein-losing enteropathies; Embolization, therapeutic; Heart defects, congenital; Cardiac surgical procedures; Lymphatic abnormalities

INTRODUCTION

Protein-losing enteropathy (PLE) involves the abnormal loss of serum proteins from the vascular compartment into the gastrointestinal (GI) lumen leading to a hypoproteinemic state [1,2]. The documentation of increased stool losses of $\alpha_1$-antitrypsin along with low serum albumin and $\alpha_1$-antitrypsin confirms the diagnosis [1,2]. A proposed pathophysiologic mechanism of PLE in the Fontan circulation involves increased pressure in the lymphatics (lymphangiectasis) with loss of lymph into the GI lumen i.e. lymph-losing enteropathy (LLE) [1,2]. Fontan surgery is the final stage in the univentricular repair of complex congenital heart disease (CCHD) and involves anastomosis of the inferior vena cava to the pulmonary
artery. PLE can occur anytime between 2 and 10 years after Fontan repair [3-5]. The incidence of PLE is 3–18%, equaling approximately 2,000 cases in the US and comprising a major cause of mortality [3-6]. Here we present a child with CCHD who developed severe segmental PLE for which she underwent image-guided selective GI lymphatic embolization and showed prompt and sustained clinical improvement.

CASE REPORT

A 3-year-old girl born with L-transposition of the great arteries (LTGA), ventricular inversion, ventricular septal defect, and pulmonary atresia underwent a double-switch procedure (Hemi-mustard, Rastelli and Glenn) at 15 months of age. Interestingly, the mother was also born with LTGA and ventricular inversion but had not required surgery. Post-operatively, the patient developed refractory chylothoraces, which was initially treated by non-operative maneuvers but later by pleurodesis and thoracic duct (TD) ligation. She subsequently developed chylous ascites, severe PLE (serum albumin ≤0.9 g/dL, elevated alpha-1-antitrypsin in the stool) and malnutrition despite vigorous nutritional rehabilitation. At that time, she was diagnosed with narrowing of her systemic venous baffle and resultant inferior vena caval (IVC) obstruction with mean IVC pressure of 18 mmHg (normal, 3-8 mmHg). Because of the catheterization findings, the patient underwent revision of the hemi-Mustard systemic venous baffle. On follow-up catheterization, the IVC pressure had improved to 7 mmHg, but the PLE persisted. Over the next 2 years, multiple medical and nutritional interventions failed (corticosteroids, long-chain fat-restricted diet, subcutaneous heparin, octreotide, and diuretics). She became severely malnourished, suffered multiple PLE-related complications with hypoalbuminemia (albumin nadir=0.9 g/dL), failure to thrive, hypercoagulability, and osteopenia, and required frequent albumin and intravenous immunoglobulin infusions.

Bilateral lymphangioscintigraphy (Tc99m sulfur colloid) with three-dimensional single-photon emission computed tomography (SPECT-CT) showed rapid transport from the foot centrally and documented lymphatic obstruction at the cisterna chyli, with subsequent tracer dispersion further localized on SPECT-CT and progressive accumulation of radiotracer isolated in the duodenal loop area, dynamically delineating the segmental duodenal chyle leak (Fig. 1). Upper-GI endoscopy demonstrated chylous lymphangiectasia limited to the duodenum (Fig. 2A, B). Magnetic resonance (MR) enterography revealed coarse thickening localized to the duodenal loop from the pylorus to the first part of the jejunum along with lymphangiectasia and a segmental chyle leak (Fig. 3). She was then transferred to the Children’s Hospital of Philadelphia, where MR inguinal intranodal lymphangiography revealed leakage (Fig. 4). When the dye was injected into the TD along with simultaneous endoscopic visualization of the duodenum, leakage of the dye into the duodenal lumen was demonstrated (Fig. 5). Selective glue embolization of the refluxing and leaking intestinal lymphatic trunk with n-butyl-2-cyanoacrylate (n-BCA) liquid embolic system (Trufill; Cordis Neurovascular, Miami Lakes, FL, USA) resulted in rapid reversal of the PLE over just a few weeks after the procedure (Fig. 6). Follow-up endoscopy revealed complete resolution of the chylous lymphangiectasia (Fig. 2C, D). The patient’s edema and ascites completely resolved with weight gain and catch-up growth. She has maintained normal albumin levels (>4.0 g/dL) in over 3 years of follow-up since the lymphatic embolization.
Correcting Protein-Losing Enteropathy

Fig. 1. Lymphangioscintigram and single photon emission computed tomography (SPECT). (A) Bilateral Tc99m sulfur colloid lower-extremity lymphangioscintigraphy showing rapid transport from foot injection sites central to the cisterna chyli (arrow) and later tracer dispersion. (B) SPECT localizing an abnormal area in the duodenal loop (arrow) corresponding to thickening with a loss of wall (arrows) throughout the duodenal loop as seen on magnetic resonance enterography.

Fig. 2. Gastrointestinal endoscopy image showing chylous lymphangiectasia localized to the duodenal loop (A, B) and complete resolution after the procedure (C, D).
DISCUSSION

PLE in CCHD most commonly occurs after Fontan repair. It has also been reported to occur after Glenn repair, in cases of central venous obstruction, and in cases of complete lymphatic obstruction [7-9]. Lymphatic obstruction may indeed be the common factor in the development of PLE in CCHD [7-9]. Conventional treatment strategies have included attempts to halt intestinal protein leaks and improving cardiovascular physiology using medications, the creation of fenestration, atrial pacing, or heart transplantation [10].
After the Fontan procedure, the central venous pressure (CVP) increases, typically by 12–16 mmHg, but in instances in which the CVP is substantially increased, the lymph pressure and resistance can increase to extremely high levels [11]. The pathophysiologic sequence of events following elevated CVP consists of increased lymphatic pressure and lymph flow, followed by lymphatic collateral formation and progressive resistance to lymph return to the central veins, leading to an increase in capillary filtration and lymph production [2,11]. In some patients, the increase in intestinal lymphatic pressure can also cause localized rupture of the lymphatics in the intestinal mucosa, resulting in lymph leaking into the body cavities (chylothorax, chylopericardium, chyloous ascites) or through the intestinal mucosa into the lumen [11]. The loss of chyle including circulating immune cells and proteins resulting in PLE is called LLE. If the albumin production does not compensate for the losses, LLE results in hypoalbuminemia [1,2,11]. It is still not fully understood why only some patients after

![Fig. 5. Simultaneous blue dye injection in the thoracic duct along with endoscopic visualization of the duodenum demonstrating leakage of the dye into the duodenal lumen.](image)

![Fig. 6. (A) Conventional lymphangiogram showing the stump of the thoracic duct (TD) and the intestinal trunk prior to embolization. (B) After embolization of the intestinal lymphatic trunk with 0.5 cc of TrueFill glue, a glue cast is visible in the intestinal trunk. A microcatheter remains in the remnant of the TD.](image)
Fontan repair subsequently develop PLE [8,12,13]. Further implication of the lymphatic system in the etiopathogenesis has been documented on GI endoscopic biopsies showing intestinal lymphangiectasia [14]. LLE and PLE patients can have profound nutritional disorders, abnormal bone mineral density, severe lymphopenia, decreased CD4 and CD3 T cell counts, and other immune consequences [15-17]. In patients with CCHD, the addition of nutritional and infectious challenges would be an added burden increasing the morbidity and mortality rates. Traditional management includes diuretics, supplemental protein, steroids, and heparin, but their efficacy remains controversial [10]. Liver lymphangiography and embolization of the hepatic lymphatic was first described in a patient in whom lymphorrhea resolved [18]. In a series of eight patients with CCHD and PLE, selective lymphatic embolization improved symptoms and albumin levels [19,20].

We hypothesized that our patient’s IVC obstruction coupled with the ligated TD precipitated the development of lymphatic fistulous connections to her duodenum along with lymphatic rupture with a resulting copious lymph leak. The pathogenesis of PLE in this case could be similar to Fontan physiology and secondary to a combination of underlying CCHD with an increased systemic pressure.

Noninvasive bipedal or 4-limb SPECT-CT and GI endoscopy are useful for the initial screening of chylous reflux and LLE. Subsequently, dynamic contrast-enhanced intranodal MR lymphangiography can accurately delineate the extent of chylous reflux. MR-guided direct central lymphatic puncture and selective catheter embolization with n-BCA (Trufill) can then be performed. Liver lymphangiography can identify additional lymphatics requiring embolization by demonstrating reflux of lymph from the liver into the duodenum through abnormal hepatoduodenal lymphatic communication [18,19]. These may be aggravated by congestive liver disease, which further promotes liver lymph flow into the already overloaded cisterna chyli and TD. In such situations, percutaneous transabdominal TD catheterization and interruption of the lymphatic flow by lymphatic embolization can abolish this retrograde flow into the GI tract and decrease the enteropathy [19]. These imaging modalities can monitor and guide interventional lymphatic sclerosis, and decompressing lymphatic shunts into the pulmonary vein or left atrium, thereby mobilizing excessive TD lymph flow into the low-pressure left heart and reversing the lymphatic complications [11,13]. Repeating the SPECT-CT and GI endoscopy after the intervention can monitor the procedure’s clinical efficacy.

REFERENCES

1. Greenwald DA. Protein-losing gastroenteropathy. In: Feldman M, Friedman L, Brandt L, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease. 10th ed. Philadelphia: Saunders, 2016:464-70.
2. Levitt DG, Levitt MD. Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states. Clin Exp Gastroenterol 2017;10:147-68.
3. Johnson JN, Driscoll DJ, O’Leary PW. Protein-losing enteropathy and the Fontan operation. Nutr Clin Pract 2012;27:375-84.
4. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998;115:1063-73.
5. Malcic I, Sauer U, Stern H, Kellerer M, Kühlein B, Locher D, et al. The influence of pulmonary artery banding on outcome after the Fontan operation. J Thorac Cardiovasc Surg 1992;104:743-7.
6. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol 2014;64:54-62.

7. Gleason WA Jr, Roodman ST, Laks H. Protein-losing enteropathy and intestinal lymphangiectasia after superior vena cava-right pulmonary artery (Glenn) shunt. J Thorac Cardiovasc Surg 1979;77:843-6.

8. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011;21:363-77.

9. Meadows J, Gauvreau K, Jenkins K. Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease. Congenit Heart Dis 2008;3:269-76.

10. Rychik J, Spray TL. Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002;5:3-11.

11. James H, Witte MH, Bernas M, Barber B. Proposal for prevention or alleviation of protein/lymph-losing enteropathy (PLE/LLE) after Fontan circulation treatment of univentricular hearts: restoration of lymph balance with a “lymphatic right-to-left shunt.”. Lymphology 2016;49:114-27.

12. Petersen VP, Hastrup J. Protein-losing enteropathy in constrictive pericarditis. Acta Med Scand 1963;173:40140.

13. António M, Gordo A, Pereira C, Pinto F, Fragata I, Fragata J. Thoracic duct decompression for protein-losing enteropathy in failing Fontan circulation. Ann Thorac Surg 2016;101:4370-3.

14. Connor FL, Angelides S, Gibson M, Larden DW, Roman MR, Jones O, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy. Pediatrics 2003;112(3 Pt 1):e242-7.

15. Magdo HS, Stillwell TL, Greenhawt MJ, Stringer KA, Yu S, Fifer CG, et al. Immune abnormalities in Fontan protein-losing enteropathy: a case-control study. J Pediatr 2015;167:331-7.

16. Müller C, Wolf H, Göttlicher J, Zielinski CC, Eibl MM. Cellular immunodeficiency in protein-losing enteropathy. Predominant reduction of CD3+ and CD4+ lymphocytes. Dig Dis Sci 1991;36:116-22.

17. Goldberg DJ, Dodds K, Avitabile CM, Glatz AC, Brodsky JL, Semeao EJ, et al. Children with protein-losing enteropathy after the Fontan operation are at risk for abnormal bone mineral density. Pediatr Cardiol 2012;33:1264-8.

18. Guez D, Nadolski GJ, Pukenas BA, Itkin M. Transhepatic lymphatic embolization of intractable hepatic lymphorrhea. J Vasc Interv Radiol 2014;25:149-50.

19. Itkin M, Piccoli DA, Nadolski G, Rychik J, DeWitt A, Pinto E, et al. Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol 2017;69:2929-37.

20. Latson L. Once more unto the breach: a new treatment paradigm for protein-losing enteropathy. J Am Coll Cardiol 2017;69:2938-40.